The treatment landscape of metastatic prostate cancer

被引：90

作者：

Yamada, Yasutaka ^{[1
]}

Beltran, Himisha ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Sm 758, Boston, MA 02115 USA

来源：

CANCER LETTERS | 2021年 / 519卷

基金：

日本学术振兴会;

关键词：

Metastatic prostate cancer; Castration resistance; Androgen receptor pathway inhibitor; Treatment sequencing; Precision medicine; MITOXANTRONE PLUS PREDNISONE; QUALITY-OF-LIFE; PHASE-III TRIAL; DOUBLE-BLIND; RADIUM-223; DICHLORIDE; ABIRATERONE ACETATE; ZOLEDRONIC ACID; BONE METASTASES; INCREASED SURVIVAL; OPEN-LABEL;

D O I：

10.1016/j.canlet.2021.06.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment landscape of metastatic prostate cancer has evolved significantly over the past two decades. Several landmark phase 3 trials led to new drug approvals and rapid changes in therapy options for patients, including drugs with distinct mechanisms of action (e.g., hormonal, chemotherapy, radionuclide, immunotherapy, and targeted therapies). Therapies initially developed in later stages of the disease (metastatic castration resistant prostate cancer) have started to move earlier in the prostate cancer continuum, with new standards of care for metastatic hormone naive prostate cancer and non-metastatic castration resistant prostate cancer. Overall, patients are living longer with a better quality of life. However, despite these significant advances, prostate cancer remains a leading cause of cancer death globally. Disease heterogeneity and the emergence of therapy resistance remain significant barriers, and the identification and application of molecular biomarkers to guide the choice and sequencing of systemic agents are still in early stages. Here we discuss the current treatment landscape of metastatic prostate cancer, clinical challenges, and the emerging role of molecular biomarkers for targeting biologic subsets of advanced disease and co-targeting heterogenous resistance patterns.

引用

页码：20 / 29

页数：10

共 100 条

[21]

Dalesio O, 2000, LANCET, V355, P1491

[22] Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer [J].

Davis, Ian D. ;

Martin, Andrew J. ;

Stockler, Martin R. ;

Begbie, Stephen ;

Chi, Kim N. ;

Chowdhury, Simon ;

Coskinas, Xanthi ;

Frydenberg, Mark ;

Hague, Wendy E. ;

Horvath, Lisa G. ;

Joshua, Anthony M. ;

Lawrence, Nicola J. ;

Marx, Gavin ;

McCaffrey, John ;

McDermott, Ray ;

McJannett, Margaret ;

North, Scott A. ;

Parnis, Francis ;

Parulekar, Wendy ;

Pook, David W. ;

Reaume, M. Neil ;

Sandhu, Shahneen K. ;

Tan, Alvin ;

Tan, T. Hsiang ;

Thomson, Alastair ;

Tu, Emily ;

Vera-Badillo, Francisco ;

Williams, Scott G. ;

Yip, Sonia ;

Zhang, Alison Y. ;

Zielinski, Robert R. ;

Sweeney, Christopher J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) :121-131

[23] Olaparib for Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, J. ;

Mateo, J. ;

Fizazi, K. ;

Saad, F. ;

Shore, N. ;

Sandhu, S. ;

Chi, K. N. ;

Sartor, O. ;

Agarwal, N. ;

Olmos, D. ;

Thiery-Vuillemin, A. ;

Twardowski, P. ;

Mehra, N. ;

Goessl, C. ;

Kang, J. ;

Burgents, J. ;

Wu, W. ;

Kohlmann, A. ;

Adelman, C. A. ;

Hussain, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) :2091-2102

[24] Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss [J].

de Bono, Johann S. ;

De Giorgi, Ugo ;

Rodrigues, Daniel Nava ;

Massard, Christophe ;

Bracarda, Sergio ;

Font, Albert ;

Arranz Arija, Jose Angel ;

Shih, Kent C. ;

Radavoi, George Daniel ;

Xu, Na ;

Chan, Wai Y. ;

Ma, Han ;

Gendreau, Steven ;

Riisnaes, Ruth ;

Patel, Premal H. ;

Maslyar, Daniel J. ;

Jinga, Viorel .

CLINICAL CANCER RESEARCH, 2019, 25 (03) :928-936

[25] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[26] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[27] Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer [J].

de Wit, Ronald ;

de Bono, Johann ;

Sternberg, Cora N. ;

Fizazi, Karim ;

Tombal, Bertrand ;

Wuelfing, Christian ;

Kramer, Gero ;

Eymard, Jean-Christophe ;

Bamias, Aristotelis ;

Carles, Joan ;

Iacovelli, Roberto ;

Melichar, Bohuslav ;

Sverrisdottir, Asgerdur ;

Theodore, Christine ;

Feyerabend, Susan ;

Helissey, Carole ;

Ozatilgan, Ayse ;

Geffriaud-Ricouard, Christine ;

Castellano, Daniel ;

de Wit, Ronald ;

de Bono, Johann ;

Sternberg, Cora N. ;

Fizazi, Karim ;

Tombal, Bertrand ;

Wulfing, Christian ;

Kramer, Gero ;

Eymard, Jean-Christophe ;

Bamias, Aristotelis ;

Carles, Joan ;

Iacovelli, Roberto ;

Melichar, Bohuslav ;

Sverrisdottir, Asgerour ;

Theodore, Christine ;

Feyerabend, Susan ;

Helissey, Carole ;

Ozatilgan, Ayse ;

Geffriaud-Ricouard, Christine ;

Castellano, Daniel .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (26) :2506-2518

[28] The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer [J].

Deegen, Petra ;

Thomas, Oliver ;

Nolan-Stevaux, Olivier ;

Li, Shyun ;

Wahl, Joachim ;

Bogner, Pamela ;

Aeffner, Famke ;

Friedrich, Matthias ;

Liao, Michael Z. ;

Matthes, Katja ;

Rau, Doris ;

Rattel, Benno ;

Raum, Tobias ;

Kufer, Peter ;

Coxon, Angela ;

Bailis, Julie M. .

CLINICAL CANCER RESEARCH, 2021, 27 (10) :2928-2937

[29] Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA [J].

Eisenberger, Mario ;

Hardy-Bessard, Anne-Claire ;

Kim, Choung Soo ;

Geczi, Lajos ;

Ford, Daniel ;

Mourey, Loic ;

Carles, Joan ;

Parente, Phillip ;

Font, Albert ;

Kacso, Gabriel ;

Chadjaa, Mustapha ;

Zhang, Wenping ;

Bernard, John ;

de Bono, Johann .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) :3198-+

[30] Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer [J].

Fendler, Wolfgang P. ;

Weber, Manuel ;

Iravani, Amir ;

Hofman, Michael S. ;

Calais, Jeremie ;

Czernin, Johannes ;

Ilhan, Harun ;

Saad, Fred ;

Small, Eric J. ;

Smith, Matthew R. ;

Perez, Paola M. ;

Hope, Thomas A. ;

Rauscher, Isabel ;

Londhe, Anil ;

Lopez-Gitlitz, Angela ;

Cheng, Shinta ;

Maurer, Tobias ;

Herrmann, Ken ;

Eiber, Matthias ;

Hadaschik, Boris .

CLINICAL CANCER RESEARCH, 2019, 25 (24) :7448-7454

← 1 2 3 4 5 6 7 8 9 10 →